Skip to main content

Compass Therapeutics, Inc.

corporate_fare Company Profile

Compass Therapeutics, Inc.

CMPX·NASDAQ·Life Sciences·CIK 0001738021

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing proprietary antibody-based therapeutics for various human diseases. The company's scientific approach centers on the relationship between angiogenesis, the immune system, and tumor growth. Its pipeline of novel product candidates is designed to target multiple critical biological pathways necessary for an effective anti-tumor response. These pathways include modulating the microvasculature through angiogenesis-targeted agents, inducing a potent immune response via activators on effector cells in the tumor microenvironment, and alleviating immunosuppressive mechanisms used by tumors to evade immune surveillance. The company plans to advance its product candidates through clinical development and commercialization as both standalone therapies and in combination with proprietary pipeline antibodies, based on supportive clinical and nonclinical data. The pipeline consists of four clinical product candidates. The lead candidate, tovecimig (formerly CTX-009), is a bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). Tovecimig is currently being evaluated in a randomized Phase 2/3 trial in the United States in combination with paclitaxel in patients with biliary tract cancer (BTC) who received one prior treatment regimen. This trial met its primary endpoint with an overall response rate (ORR) of 17.1% for tovecimig in combination with paclitaxel, including one complete response, compared to a 5.3% ORR for paclitaxel alone. This difference was statistically significant with p=0.031. The second program, CTX-471, is an agonistic antibody targeting TNFRSF9 (CD-137 or 4-1BB). The third program, CTX-8371, is a bispecific antibody targeting programmed cell death protein-1 (PD-1) and its ligand PD-L1. The fourth program, CTX-10726, is a bispecific antibody targeting PD-1 and VEFG-A.

Compass Therapeutics, Inc. (NASDAQ:CMPX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for CMPX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CMPX spans 8-K, 10-Q, DEF 14A, 10-K.

Recent high-impact activity:

  • Compass Therapeutics Receives Nasdaq Deficiency Letter After 30 Days Below $1.00
  • Compass Q3 Loss Widens to $27.2M as Tovecimig Manufacturing Spend Jumps; $163M Cash Runs Into 2028
  • Compass Q3: $163M Cash Into 2028, Loss Widens to $27.2M as FDA Standoff Persists
  • FDA Demands Survival Trial Before Tovecimig BLA, Delaying Compass Approval
  • Compass Q2: Tovecimig Final ORR Reaches 18%, Cash Runway Into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$66.49M
Op. Cash Flow
-$49.14M
Free Cash Flow
-$49.17M
Operating Income
-$72.84M
Cash & Equivalents
$30.64M
Debt / Equity
0.00×
Shares Outstanding
178.32M sh
Source: 10-K · filed 2026-03-05 · accession 0001171843-26-001337

Short Interest & Short Volume

18.93 days to cover

FINRA reported short interest of 40,787,255 shares in CMPX as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 39.5% of CMPX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)40,787,255 shares as of October 30, 2026
Change vs prior period▼ 2.5%
Days to cover18.93 at avg daily volume of 2,154,483
Daily short volume (FINRA facilities)39.5% of 741,114 shares on November 20, 2026
5-day average short volume41.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$0.6726 -2.27% today
52-week range · as of 2026-11-20 $0.57 – $6.88
Market cap
$123.94M
Volume
1.8M (0.8× avg)
3-mo avg 2.3M
Live data · 2026-11-21 17:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CMPX - Latest Insights

CMPX
Nov 20, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6745
Real-time Price: $0.6726 info
Change: -$0.0019 (-0.28%) info
Market Cap: $123.937M info
CMPX
Nov 09, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.760
Real-time Price: $0.6726 info
Change: -$0.0874 (-12%) info
Market Cap: $123.937M info
CMPX
Nov 09, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.760
Real-time Price: $0.6726 info
Change: -$0.0874 (-12%) info
Market Cap: $123.937M info
CMPX
Sep 22, 2026, 8:30 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $1.58
Real-time Price: $0.6726 info
Change: -$0.9074 (-57%) info
Market Cap: $123.937M info
CMPX
Aug 06, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.6726 info
Change: -$1.26 (-65%) info
Market Cap: $123.937M info
CMPX
Aug 06, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.94
Real-time Price: $0.6726 info
Change: -$1.26 (-65%) info
Market Cap: $123.937M info
CMPX
Aug 06, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.93
Real-time Price: $0.6726 info
Change: -$1.26 (-65%) info
Market Cap: $123.937M info
CMPX
Jul 01, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.18
Real-time Price: $0.6726 info
Change: -$1.51 (-69%) info
Market Cap: $123.937M info
CMPX
May 21, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.91
Real-time Price: $0.6726 info
Change: -$1.24 (-65%) info
Market Cap: $123.937M info
CMPX
May 05, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.6726 info
Change: -$1.25 (-65%) info
Market Cap: $123.937M info
CMPX
Apr 29, 2026, 8:08 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $0.6726 info
Change: -$1.20 (-64%) info
Market Cap: $123.937M info
CMPX
Apr 27, 2026, 12:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1.98
Real-time Price: $0.6726 info
Change: -$1.30 (-66%) info
Market Cap: $123.937M info
CMPX
Apr 27, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $0.6726 info
Change: -$3.13 (-82%) info
Market Cap: $123.937M info
CMPX
Apr 27, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.80
Real-time Price: $0.6726 info
Change: -$3.13 (-82%) info
Market Cap: $123.937M info
CMPX
Apr 24, 2026, 4:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.60
Real-time Price: $0.6726 info
Change: -$4.93 (-88%) info
Market Cap: $123.937M info
CMPX
Mar 05, 2026, 7:30 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.73
Real-time Price: $0.6726 info
Change: -$5.06 (-88%) info
Market Cap: $123.937M info
CMPX
Mar 05, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.73
Real-time Price: $0.6726 info
Change: -$5.06 (-88%) info
Market Cap: $123.937M info
CMPX
Jan 06, 2026, 8:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.07
Real-time Price: $0.6726 info
Change: -$4.40 (-87%) info
Market Cap: $123.937M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets